Principal Investigators: Laurence Huang, UCSF; William Worodria, Makerere University; Lucian (Luke) Davis, UCSF; Adithya Cattamanchi, UCSF; Nicholas Walter
Investigators: Charles Everett, UCSF; Christina Yoon, UCSF
Coordinator: Irene Ayakaka, IDRC
Funded By: National Institute of Health
International HIV-associated Opportunistic Pneumonias (IHOP) Study
This is an NIH-funded prospective study of HIV-associated pneumonia conducted in 3 cites representing the current HIV/AIDS epidemic in Africa (Kampala, Uganda) and USA (San Francisco, CA and Seattle, WA). IHOP includes clinical sites at San Francisco General Hospital, Harborview Medical Center (Seattle), and Mulago Hospital (Kampala) and involves 6 independent laboratories at the NIH, the University of California San Francisco, the University of Cincinnati, and the University of North Carolina. The IHOP Study is also part of the Lung HIV Study, an NHLBI multi-R01 consortium, with sites in both the US and sub-Saharan Africa. The goals of IHOP are to determine the frequency and mortality of HIV-associated opportunistic pneumonias in an international, multi-center, longitudinal cohort, to investigate non-invasive, molecular diagnosis of tuberculosis (TB) and Pneumocystis pneumonia (PCP), and to explore potential mechanisms for putative trimethoprim-sulfamethoxazole drug resistance in Pneumocystis.
Lung Microbiome in Cohorts of HIV-Infected Persons (Lung MicroCHIP)
This is an NIH-funded prospective study examining the lung microbiome in HIV-infected persons over the entire spectrum of HIV disease (acute/recent HIV infection, chronic HIV infection, and acute opportunistic pneumonias). Lung MicroCHIP includes 3 cohorts in San Francisco (Options, SCOPE, and IHOP) and 1 cohort in Kampala, Uganda (MIND-IHOP) and involves 2 independent laboratories at the University of California San Francisco. The Lung MicroCHIP Study is also part of the Lung HIV Microbiome Project, an NHLBI multi-R01 consortium, with sites in both the US and sub-Saharan Africa. The goals of Lung MicroCHIP are to compare the lung microbiome in subjects with and without HIV infection, to determine the effects of opportunistic pneumonia and accompanying pneumonia treatment on the lung microbiome of HIV-infected subjects, and to correlate lung microbiome composition and function with HIV-associated morbidity and mortality.